KRSA completes merger closing with Cyclerion; $380M private placement
Korsana Biosciences (KRSA) completed the closing of its merger with Cyclerion Therapeutics and the previously announced private placement of $380 million.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.